FDA Advisors Give PTSD Drug Combination a Thumbs Down

MedPage Today) — FDA’s outside experts weren’t sold on the trial data for brexpiprazole (Rexulti) as an adjunctive treatment for post-traumatic stress disorder (PTSD), sinking its prospects for approval in this setting.
In a 10-1 vote on Friday…
Read More

About The Author

Jonathan Jeriah

See author's posts